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Abstract
Background: Psoriasis is a chronic inflammatory skin disorder that shows as erythematous and scaly lesions. The
pathogenesis of psoriasis is driven by a dysregulation of the immune system which leads to an altered cytokine
production. Proinflammatory cytokines that are up-regulated in psoriasis include tumor necrosis factor alpha
(TNFa), interleukin-12 (IL-12), and IL-23 for which monoclonal antibodies have already been approved for clinical
use. We have previously documented the therapeutic applicability of targeting TNFa mRNA for RNA interference-
mediated down-regulation by anti-TNFa small hairpin RNAs (shRNAs) delivered by lentiviral vectors to xenografted
psoriatic skin. The present report aims at targeting mRNA encoding the shared p40 subunit (IL-12B) of IL-12 and
IL-23 by cellular transduction with lentiviral vectors encoding anti-IL12B shRNAs.
Methods: Effective anti-IL12B shRNAs are identified among a panel of shRNAs by potency measurements in
cultured cells. The efficiency and persistency of lentiviral gene delivery to xenografted human skin are investigated
by bioluminescence analysis of skin treated with lentiviral vectors encoding the luciferase gene. shRNA-expressing
lentiviral vectors are intradermally injected in xenografted psoriatic skin and the effects of the treatment evaluated
by clinical psoriasis scoring, by measurements of epidermal thickness, and IL-12B mRNA levels.
Results: Potent and persistent transgene expression following a single intradermal injection of lentiviral vectors in
xenografted human skin is reported. Stable IL-12B mRNA knockdown and reduced epidermal thickness are
achieved three weeks after treatment of xenografted psoriatic skin with lentivirus-encoded anti-IL12B shRNAs.
These findings mimick the results obtained with anti-TNFa shRNAs but, in contrast to anti-TNFa treatment, anti-
IL12B shRNAs do not ameliorate the psoriatic phenotype as evaluated by semi-quantitative clinical scoring and by
immunohistological examination.
Conclusions: Our studies consolidate the properties of lentiviral vectors as a tool for potent gene delivery and for
evaluation of mRNA targets for anti-inflammatory therapy. However, in contrast to local anti-TNFa treatment, the
therapeutic potential of targeting IL-12B at the RNA level in psoriasis is questioned.
Background
Psoriasis is a chronic inflammatory skin disorder gener-
ally manifesting itself as symmetrical, erythematous, and
scaling papules and plaques. The disease affects approxi-
mately 2-3% of the population worldwide and has a
negative impact on the physical wellbeing and the qual-
ity of life [1-5]. Histologically, psoriasis displays epider-
mal hyperplasia, parakeratosis, thinning of stratum
granulosum, and dilated and prominent vascularization
of the dermis associated with an increased cellular infil-
trate of immune cells. The exact cause of psoriasis is
unknown, but it is widely accepted that a dysregulated
immune system plays a pivotal role. Numerous pro-
inflammatory cytokines are up-regulated in psoriasis and
a normalization of the cytokine milieu has been shown
to improve the disease phenotype [6-10]. For example,
several inhibitors of tumor necrosis factor alpha
(TNFa), which is considered one of the primary media-
tors of immune regulation, have been developed and
proven successful in psoriasis treatment [11-13].
The pro-inflammatory cytokines interleukin-12 (IL-12)
and IL-23 are both up-regulated in lesional psoriatic
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leukins are expressed by activated denditric cells and
macrophages present in the skin, but also to some
extent by keratinocytes [17-19]. IL-12 stimulates the
production of IFN-g and the maturation of naïve T-cells
into Th1 cells [20]. IL-23 seems to play a crucial role in
the survival and proliferation of Th17 cells, leading to
the production of IL-17 and in turn the pro-inflamma-
tory cytokines TNFa,I L - 1 ,I L - 6 ,I L - 8 ,a n dI L - 2 2 .
Genetic polymorphisms in IL-12B and one of the IL-23
receptor subunits (IL-23R), have been linked to psoriasis
[21], and many of the current therapies used in treating
psoriasis, such as narrow-band UVB therapy [22] and
administration of Etanercept (soluble TNFa receptor)
[23] or Alefacept (an antagonist of T cell activation)
[24] all reduce levels of IL-23. IL-12 and IL-23 are con-
sidered important factors in initiating and driving the
Th1a n dT h17 cytokine profiles characteristic of
psoriasis.
IL-12 and IL-23 share a common subunit, the p40
subunit (encoded by the IL-12B gene) with the implica-
tion that both interleukins can be inhibited simulta-
neously. This therapeutic approach was recently
validated with the approval of the p40-targeting mono-
clonal antibody, Ustekinumab, for clinical use [25]. In a
phase III trial, Ustekinumab was shown to be more
effective and requiring fewer injections than the TNFa-
inhibitor Etanercept [26]. Although biological therapeu-
tics inhibiting cytokines have proven successful in the
treatment of moderate to severe psoriasis, there is still
an unmet need for treatments that are convenient, with-
out side-effects or contra-indications, and well tolerated,
especially for long-term treatment. Of note, the biologi-
cal therapeutics used today are administered systemi-
cally, where topically and locally administered
treatments may be more desirable in terms of reducing
systemic side-effects.
We have previously documented the therapeutic
applicability of targeting TNFa mRNA by lentiviral
delivery of anti-TNFa RNA effectors to xenografted
psoriatic skin [8]. We tested here the hypothesis that
targeting of IL-12B mRNA by RNA interference
(RNAi)-mediated degradation is therapeutically relevant.
RNAi is a natural cellular mechanism by which double-
stranded RNAs (dsRNAs) are processed into ~21-
nucleotide small interfering RNAs (siRNAs) which can
mediate sequence-specific degradation of target RNAs
[27]. If synthetic siRNA duplexes or DNA encoding
small hairpin RNAs (shRNAs) are transfected into cells
they are efficiently processed by the RNAi machinery
and enter the RNAi pathway [28,29]. Thus, potent and
specific down-regulation of a single gene can be
achieved by siRNA/shRNA delivery, and this is already a
widely established tool for gene suppression. shRNA
delivery by human immunodeficiency virus-derived len-
tiviral vectors benefits from high transduction efficiency
as well as specific and stable down-regulation of gene
expression [30] due to the inherent property of lenti-
viruses to integrate the genetic cargo into the genome.
In the current report, we describe the establishment of
a lentiviral vector platform for an easy one-step cloning
of shRNA oligonucleotides. Employing this novel lenti-
viral vector, we screened a panel of shRNAs targeting
different regions of IL-12B mRNA and identified a
potent shRNA candidate which mediated efficient
IL-12B mRNA knockdown in several in vitro assays. To
investigate the therapeutic applicability of targeting
IL-12B mRNA in psoriasis, we employed the psoriasis
xenograft transplantation model [31]. Administration of
the clinically approved p40-targeting antibody, Ustekinu-
mab, was included as a comparative control to validate
the relevance of targeting IL-12B in this model. Efficient
lentiviral transgene delivery to xenografted psoriatic skin
was demonstrated by intradermal injection of lentiviral
vectors encoding a luciferase reporter gene, and stable
and persistent luciferase expression was monitored for
more than three months. Lentiviral delivery of anti-IL-
12B shRNAs resulted in reduction of epidermal thick-
ness and reduction in IL-12B mRNA levels. However,
clinical evaluation of the psoriatic phenotype and immu-
nohistochemical examination of the skin grafts did not
indicate clinical resolution in this model. Taken
together, this suggests that RNAi-directed targeting of
IL-12B mRNA in lesional psoriatic skin is not as clini-
cally potent as targeting of TNFa-encoding mRNA [8].
Methods
Contruction of plasmids
pCCL-cPPT-PGK-Puro-WPRE-LTR-H1-MCS (desig-
nated pCCL-PGK-Puro-H1-MCS) was constructed from
pCCL-cPPT-PGK-puro-WPRE-LTR-H1-shTNFa [8]
identical to the construct reported by Raoul et al. [32]
except for the eGFP cassette being replaced by a puro-
mycin resistance cassette and the shRNA targeting
TNFa. By using two primer sets ((i) 5’-caccgtcaccgcc-
gacgtcg-3’ and 5’-ggcgcgcctcgctagcctcctagggtggtctcatacag
aactta-3’ and (ii) 5’-cctaggaggctagcgaggcgcgccgcggccgcc
accgcggtgga-3’ and 5’-cgctctagatgctgctagag-3’), two PCR
fragments were amplified from this plasmid amplifying
the two regions upstream and downstream of the
shTNFa including the flanking XhoI and the XbaI sites,
respectively. The two primers flanking the shTNFa
region were made with restriction site containing lin-
kers, so an overlap extension PCR between the two PCR
fragments would replace the shTNFa with a MCS
(AvrII, NheI and AscI). XhoI/XbaI digestion of the over-
lap PCR fragment allowed for insertion into the XhoI/
XbaI-digested pCCL-cPPT-PGK-puro-WPRE-LTR-H1-
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For each of the shRNA expression constructs, pCCL-
PGK-Puro-H1-shIL12B # 1-7, complementary sense and
antisense oligonucleotides (see table 1) were annealed by
incubation at 100°C for 5 minutes followed by room
temperature cooling. The annealed oligonucleotides
were designed to leave overhangs for cloning into the
AvrII/AscI-digested pCCL-PGK-Puro-H1-MCS vector.
For construction of psiCHECK-IL12B, a 1046-bp IL-12B
cDNA was amplified from an IL-12B ORF (IMAGE ID:
30915173, Geneservice Ltd, Cambridge, UK) with pri-
mers 5’-aaactcgagccattggactctccgtcctg-3’ and 5’-cctcca
aattttcatcctgg 3’.T h e3 ’UTR was amplified from
cDNA from total RNA from human psoriatic skin
using primers 5’-aggttctgatccaggatgaaaatttggagg-3’ and
5’-aaagcggccgcgattacaaagaagagttttt-3’.B r i e f l y ,t o t a lR N A
was purified with SV Total RNA Isolation System (Pro-
mega, Madison, WI, USA) and first-strand cDNA synth-
esis was performed with the AffinityScript™ QPCR
cDNA Synthesis Kit (Stratagene, La Jolla, California,
USA), both according to manufacturer’sp r o t o c o l .A n
overlap extension PCR with primers 5’-aaactcgagccattg-
gactctccgtcctg-3’ and 5’-aaagcggccgcgattacaaagaagagttttt-
3’ joined the two fragments, creating a 2336-bp IL-12B
cDNA that was cloned into the psiCHECK-2 vector
(Promega, Madison, WI, USA) using the XhoI/NotI
sites.
To create the lentiviral vector encoding firefly lucifer-
a s e( p L V / P G K - F L u c ) ,t h ef i r e f l yl u c i f e r a s eg e n ew a s
PCR-amplified from the commercially available pGL3-
Control vector (Promega, Madison, WI, USA) using
primers 5’-aaaggatccatggaagacgccaaaaaca-3’ and 5’-
aaactcgagttacacggcgatctttccgc-3’.T h eP C Rp r o d u c tw a s
cloned into the lentiviral vector, pCCL.WPS.PGK-Puro.
WHV (described in [33]), using the BamHI/XhoI sites,
replacing the puromycin resistance gene. To revert the
5-bp modification in the H1 promoter in the pCCL-
PGK-Puro-H1-MCS-based shRNA-expressing vectors to
the sequence of the original vector (pCCL-cPPT-PGK-
puro-WPRE-LTR-H1-shTNFa, harboring the remains of
a BglII site), an overlap extension PCR between two
fragments flanking the 5-bp region was done. For both
shRNA-encoding lentiviral vectors, the 5’ fragment was
amplified by primers 5’-ctgctgccggctctgcggcc-3’ and
5’-ggggatctgtggtctcatacagaactta-3’.T h e3 ’ fragment was
amplified using primers 5’-gttctgtatgagaccacagatccccgca
gacagatgc-3’ and 5’-ctctagcagcatctagagcg-3’ (in case of
pCCL-PGK-Puro-H1-shIL12B #5) and 5’-gttctgtatgagac
cacagatccccgatgggaacgca-3’ and 5’-ctctagcagcatctagagcg-
3’ (in case of pCCL-PGK-Puro-H1-shIL12B #6). Overlap
extension PCRs between the 5’ fragment and the 3’ frag-
m e n t sw e r ed o n eb yp r i m e r s5 ’-ctgctgccggctctgcggcc-3’
and 5’-ctctagcagcatctagagcg-3’.T h eo v e r l a pe x t e n s i o n
PCR amplicons were inserted into the original lentiviral
vectors using the XbaI and ApaI restriction sites. All
constructs were verified by sequencing with BigDye
®
Terminator v.3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA).
shRNA oligonucleotide design
The lentiviral construct encoding the irrelevant shRNA
was constructed as described in [8]. For shIL-12B #1-#7,
the loop region in the shRNAs were chosen on the basis
of that proposed by McIntyre and Fanning [34]. The
design of the shRNA oligonucleotides was to resemble
the endogenous situation of the H1 promoter and the
H1 RNA coding region (the RNA Component of
H u m a nR N a s eP ) .T h i si n c l u d e sad i s t a n c eo f2 6 - n t
between the TATA-box and the transcriptional start
site, three cytosines before the transcriptional start and
Table 1 Oligonucleotides used for creation of anti-IL12B shRNA expression cassettes
shRNA Oligonucleotide sequence (target sequences are underlined)
shIL12B #1 Sense: 5’-ctagccccctcacctgtgacacccctactcgagaaggggtgtcacaggtgaggtttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaacctcacctgtgacaccccttctcgagtaggggtgtcacaggtgaggggg-3’
shIL12B #2 Sense: 5’-ctagcccatgccagcattagcgtgcgactcgagacgcacgctaatgctggcattttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaaatgccagcattagcgtgcgtctcgagtcgcacgctaatgctggcatggg-3’
shIL12B #3 Sense: 5’-ctagcccggtcttaggctctggcaaaactcgagatttgccagagcctaagacctttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaaggtcttaggctctggcaaatctcgagttttgccagagcctaagaccggg-3’
shIL12B #4 Sense: 5’-ctagcccggaatttggtccactgataactcgagatatcagtggaccaaattcctttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaaggaatttggtccactgatatctcgagttatcagtggaccaaattccggg-3’
shIL12B #5 Sense: 5’-ctagcccgcagacagatgcaaagaaaactcgagatttctttgcatctgtctgctttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaagcagacagatgcaaagaaatctcgagttttctttgcatctgtctgcggg-3’
shIL12B #6 Sense: 5’-ctagcccgatgggaacgcaagagatactactcgagaagtatctcttgcgttcccatctttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaagatgggaacgcaagagatacttctcgagtagtatctcttgcgttcccatcggg-3’
shIL12B #7 Sense: 5’-ctagcccgggccttcatgctatttaaactcgagattaaatagcatgaaggccctttttggaaa-3’
Antisense: 5’-cgcgtttccaaaaagggccttcatgctatttaatctcgagtttaaatagcatgaaggcccggg-3’
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signal [35]. The cleavage of the shRNA transcript at the
termination site is after the second uridine yielding a
2-nt 3’ overhang resembling that of endogenously pro-
cessed pre-miRNAs [29]. shIL12B #1 was adapted from
an siRNA reported by Flynn et al. to target a sequence
of the murine IL-12B with high homology to the human
sequence [36]. The target sequence was modified to
match the human sequence. shIL12B #2 was adapted
from an siRNA that has been reported by Borg et al. to
efficiently target human IL-12B [37]. shIL12B #3-#7
were predicted by online algorithms: shIL12B #3-#5 by
Dharmacon’s siDESIGN, shIL12B #6 by InvivoGen
siRNA Wizard, and shIL12B #7 by Qiagen’sB i o P r e d S i .
See table 1 for shRNA oligonucleotide sequences.
Cell culturing
HeLa, HEK293, and 293T cells were cultured at stan-
dard conditions at 37˚C in 5% (v/v) CO2 and maintained
in Dulbecco’s modified Eagle’sm e d i u m( C a m b r e x ,
Verviers, Belgium) supplemented with 10% fetal calf
serum, penicillin (100 U/ml), streptomycin (0.1 mg/ml),
and L-glutamine (265 mg/l).
Dual-Luciferase Reporter Assay
For co-transfection experiments, HEK293 cells were
seeded in 24-well plates (1.9 × 10
4 cells/well) one day
before transfection. Co-transfections were performed
with a total of 0.4 μgD N A( 0 . 3 6μgs h R N A - e n c o d i n g
lentiviral vector and 0.04 μg psiCHECK-IL12B vector)
using FuGENE-6 (Roche, Basel, Switzerland) according
to the manufacturer’s protocol. Forty-eight hours post-
transfection, Renilla and Firefly Luciferase activities were
analyzed by the use of the Dual-Luciferase
® Reporter
Assay System (Promega, Madison, WI, USA) according
to the manufacturer’s protocol. Reactions were carried
out in 96-well plates and luminescence readings were
performed in a multisample platereading luminometer
(Berthold, Bad Wild-bad, Germany). Renilla Luciferase
activity was normalized to Firefly Luciferase activity and
presented relative to the negative vehicle control
(pCCL-PGK-Puro-H1-MCS).
In transduction studies of shRNA-encoding lentiviral
vectors, HEK293 cells were seeded in 24-well plates (1.9
×1 0
4 cells/well) and transduced at an MOI of 10.
The viral supernatant was supplemented with 8 μg/ml
polybrene (Sigma-Aldrich, Milwaukee, WI). One day
post-transduction, transfections with 0.04 μgp s i -
CHECK-IL12B vector using FuGENE-6 (Roche, Basel,
Switzerland) were performed according to the manufac-
turer’s protocol and luciferase activities were measured
forty-eight hours post-transfection as described above.
To make cell lines with stable expression of shRNAs
f r o mas i n g l el e n t i v i r a li n s e r t i o n ,H E K 2 9 3c e l l sw e r e
seeded in 6-well plates (5 × 10
4 cells/well) one day
before transduction. Lentiviral supernatants were serially
diluted and supplemented with 8 μg/ml polybrene
(Sigma-Aldrich, Milwaukee, WI). Transduced cells were
grown in 1 μg/ml puromycin-containing medium
(Sigma-Aldrich, Milwaukee, WI) after which cells from
a well with a low colony-count were pooled and allowed
to expand. Ten days post-transduction, these cells were
seeded in 24-well plates (1.9 × 10
4 cells/well) and trans-
fected the following day with 0.04 μg psiCHECK-IL12B
vector using FuGENE-6 (Roche, Basel, Switzerland)
according to the manufacturer’s protocol and luciferase
activities were measured forty-eight hours post-transfec-
tion as described above. All dual luciferase assay experi-
ments were performed at least in triplicates.
Generation of the IL12B-expressing HeLa cell line,
HeLa-IL12B
The Sleeping Beauty DNA transposon vector encoding
IL-12B was created by amplification of IL-12B cDNA
from the psiCHECK-IL12B vector with primers
5’-aaagcggccgcccattggactctccgtcctg-3’ and 5’-aaagc
ggccgcgattacaaagaagagttttt-3’. eGFP was excised using
NotI from a biscitronic DNA transposon vector, pT2/
CMV-eGFP(s).SV40-neo. The IL-12B PCR amplicon was
inserted into the vector in the sense orientation using
the NotI sites. Transposition in the HeLa cell line was
performed in 6-well plates into which 2 × 10
5 HeLa
cells were seeded. Twenty-four hours later, the cells
were co-transfected with 0.5 μg transposon vector and
0.5 μg of transposase-encoding vector (SB100X) using
FuGene6 (Roche, Basel, Switzerland) according to man-
ufacturer’s protocol. The cells were selected for positive
transposition by G418-supplemented medium (600 μg/
mL) for ten days. From a well with a low colony-count,
single clones were isolated to separate dishes and
expanded. IL-12B mRNA expression analysis was per-
formed by purification of RNA using the RNeasy Mini
Kit (Qiagen, Valencia, California, USA) followed by first
strand cDNA synthesis using AffinityScript™ QPCR
cDNA Synthesis Kit (Stratagene, La Jolla, California,
USA) according to manufacturer’sp r o t o c o l .I L - 1 2 B
mRNA expression was confirmed by IL12B-specific PCR
on first strand cDNA. A single HeLa-IL12B clone was
chosen for subsequent experiments.
Lentiviral production
Lentiviral vectors were produced in 293T cells which
were seeded in 10-cm dishes (4 × 10
6 cells/well).
Twenty-four hours after, cells were calcium phosphate
transfected with 3.75 μg pMD.2G, 3 μgp R S V - R e v ,
13 μgp M D G P - L g / R R E ,a n d1 3μgl e n t i v i r a lt r a n s f e r
vector. Forty-eight hours post-transfection, the viral
supernatant was harvested and filtered in 0.45 μm filters
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many). The resulting lentiviral vectors were designated
LV-shRNA (e.g. LV-shIL12B #6). Colony-forming titer
assays were performed on HEK293 cells seeded in 6-
well plates (5 × 10
4 cells/well) one day before transduc-
tion. Lentiviral supernatants were serially diluted and
supplemented with 8 μg/ml polybrene (Sigma-Aldrich,
Milwaukee, WI). Transduced cells were grown in 1 μg/
ml puromycin-containing medium (Sigma-Aldrich, Mil-
waukee, WI) for seven days after which the number of
colonies were counted in the wells. For in vivo transduc-
tions of xenografted human skin, the lentiviral vectors
were ultra-centrifuged for 2 hours (4°C at 25000 r.p.m.)
in a SW28 rotor (Beckman Coulter, Fullerton, CA,
USA). Virus pellets were resuspended overnight in PBS
(without CaCl2 and MgCl2) at 4°C in a volume of 1/300
of the original volume. The lentiviral vector yield was
determined by measurements of p24 Gag protein using
a HIV-1 p24 Antigen ELISA Kit (ZeptoMetrix, Buffalo,
NY) according to manufacturer’s protocol.
In vivo treatment of xenografted human skin by shIL12B-
encoding lentiviral vectors and by p40-targeting
antibodies
For evaluation of luciferase expression in human skin
transduced with luciferase-encoding lentiviral vectors,
skin grafts from a patient undergoing plastic surgery
were obtained. For the evaluation of the effect of IL-12B
knockdown in human psoriatic skin by shIL12B #6 or
Ustekinumab (Stelera
®, Janssen-Cilag, Birkerød, Den-
mark), psoriatic skin biopsies were obtained from seven
patients with moderate to severe plaque psoriasis. The
psoriasis of the participants was untreated for at least
one month prior to biopsy acquisition. Informed patient
consent was obtained and the study was approved by
the Central Ethical Committee and conducted according
to the Declaration of Helsinki protocols. Animal studies
were carried out with permission from the Danish
Experimental Animal Inspectorate. The xenotransplanta-
tion procedure was as follows: each skin biopsy, contain-
ing both epidermis and dermis, was split into several
grafts (each 1.5 × 1.5 × 0.05 cm) and transplanted onto
C.B-17 severe combined immunodeficient (SCID) mice,
6-8 weeks old (Taconic M & B, Silkeborg, Denmark), as
described in [7]. Shortly, the mice were anesthetized
prior to surgery by a subcutaneous injection of Ketami-
nol (ketamine, 100 mg/kg; Intervet, Skovlunde,
Denmark) and Narcoxyl (xylazine, 10 mg/kg; Intervet,
Skovlunde, Denmark). The back was shaved and part of
the exposed skin removed. The grafts were sutured with
absorbable 6-0 suture (Caprosyn, Covidien, Dublin,
Ireland) and covered with Xeroform dressings (Sher-
wood Medical Company; Markham, Ontario, Canada)
for one week. The mice were kept under pathogen-free
conditions throughout the study. The grafts healed for
10 days before treatment initiation. To evaluate lucifer-
ase expression in skin grafts and the effect of IL-12B
knockdown by shRNA delivery, 150 μlL V - P G K - F l u c ,
LV-shIL12B #6 or LV-shIrrelevant were administered
intradermally into the grafts as a single treatment (LV-
PGK-Fluc was injected at a dose of 6.45 μgp 2 4G a gi n
150 μL and the shRNA-encoding lentiviral vectors were
injected at a dose of 30.1 ± 23.4 μg p24 Gag in 150 μL).
As a positive control in the IL-12B knockdown study,
Betnovat
® (1 mg/g cream, GlaxoSmithKline Pharma)
was applied once daily for the duration of the three-
week treatment. As an additional negative control, a
group of mice was left untreated. To evaluate the effect
of p40 inhibition by treating the mice with the p40-
targeting antibody, Ustekinumab, 200 μLU s t e k i n u m a b
(0.9 mg/kg) or 200 μL negative control (0.9%sodium
chloride solution) were administered to the mice intra-
peritoneally once weekly for the duration of the three-
week treatment.
Evaluation of bioluminescence
Three mice receiving lentiviral vectors encoding firefly
luciferase and one mouse left untreated were analyzed
on day 3, 7, 11, 15, 18, 22, 37, 53, 80, and 98 for biolu-
minescence. Briefly, the mice were injected intraperito-
neally with 200 μL luciferin (15 mg/mL) (Synchem
OHG, Felsberg/Altenburg, Germany) and subsequently
anesthetized with 3.75% isoflurane (Forene
®, Abbott
Scandinavia AB, Solna, Sweden). Anesthesia was main-
tained at 2% isoflurane while bioluminescence was ana-
lyzed using an IVIS
® Spectrum (Caliper Life Sciences,
Hopkinton, MA, USA) with the software Living Image
®
4.0. Ten images were acquired at an interval of 2 min-
utes and peak-intensity images were selected for subse-
quent analysis. For quantification of bioluminescence
from each skin graft, a region of interest was set with a
lower threshold of 25% of maximum luminescence and
average luminescence was measured within this region.
Xenograft evaluation
The semi-quantitative clinical psoriasis scores were
assessed for each psoriatic xenograft twice weekly in a
blinded fashion and scored according to the average of
the following clinical signs: scaliness, induration and
erythema. The parameters were scored using a four-
point scale: 0, complete lack of cutaneous involvement;
1, slight involvement; 2, moderate involvement; 3, severe
involvement. On this scale from 0 to 3, a maximal score
of 3 represents severe scale, induration and erythema of
the xenografted psoriatic skin. After treatment, biopsies
from the centre of the graft were obtained and paraffin-
embedded. Employing standard methods, sections were
stained histochemically with haematoxylin and eosin.
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places from the stratum corneum to the deepest part of
the rete pegs on three equally distant cut sections and
the average value was calculated.
Quantitative RT-PCR
Skin biopsies from in vivo-transduced xenografted psor-
iatic skin were snap-frozen in liquid nitrogen and stored
at -80°C. Biopsies were transferred to RNAlater-ICE
(Ambion, Austin, TX, USA) and stored at -20°C for
twenty-four hours prior to RNA isolation. From both
in vitro cultured cells and skin biopsies, total RNA was
extracted using the SV Total RNA Isolation System
(Promega, Madison, WI, USA) according to manufac-
turer’s protocol. The skin biopsies were homogenized in
the lysis buffer for 2 × 2 minutes at 25 Hz using a Tis-
sueLyser (Qiagen, Valencia, California, USA). Isolated
RNA was dissolved in nuclease-free water and stored at
-80°C. First strand cDNA synthesis was performed using
the iScript cDNA Synthesis Kit (Bio-Rad, Hercules,
California, USA) according to manufacturer’sp r o t o c o l .
Lentiviral transcripts were detected using a PCR amplify-
ing part of the puromycin resistance gene and the
woodchuck hepatitis element using primers 5’-caccgt
caccgccgacgtcg-3’ (s) and 5’- gtcccggaaaggagctgac-3’ (as).
IL-12B mRNA levels were assessed by qRT-PCR employ-
ing the TaqMan
® Gene Expression Master Mix (Applied
Biosystems, Foster City, CA) according to manufacturer’s
protocol. IL-12B mRNA expression was determined
using IL-12B primers and probes (FAM-labeled MGB-
probes) (Hs01011518_m1, Applied Biosystems, Foster
City, CA). IL-12B mRNA levels were normalized to the
expression of the reference gene ribosomal protein, large,
P0 (RPLP0) using RPLP0-specific primers (FAM-labeled
MGB-probes) (Hs99999902_ml, Applied Biosystems, Fos-
ter City, CA). Expression of each gene was analyzed in at
least duplicates using a LightCycler 480 (Roche, Basel,
Switzerland). PCR conditions were 10 minutes at 95°C,
45 cycles of 15 seconds at 95°C and 60 seconds at 60°C.
For all qPCR experiments, relative mRNA levels were
determined using the relative standard curve method.
Briefly, a standard curve for each gene was made from
serial dilutions of the cDNA. The standard curve was
then used to calculate relative amounts of target mRNA
in the samples. Mean mRNA values were calculated and
the data summarized as mean + SEM.
Immunohistochemical stainings
Tissue sections were immuno-stained with monoclonal
rabbit anti-human antibodies against CD4 (clone SP 35,
Cell Marque, Rocklin, CA, USA) and Ki-67 (Clone SP6,
Spring Bioscience, Pleasanton, CA, USA), monoclonal
mouse anti-human CD8 (M7103, Dako, Glostrup, Den-
mark), polyclonal goat anti-human antibodies against
Elafin/SKALP (an epithelial proteinase inhibitor)
(HP9025, Hycult Biotechnology, Uden, the Netherlands)
and human b-defensin (hBD)-2 (an antimicrobial pep-
tide) (500-P161G, Peprotech, London, UK). Elafin/
SKALP and hBD-2 are both present in psoriasis skin
but not in normal or atopic dermatitis skin [38]. Prior
to staining, antigens were retrieved in Tris-EGTA (TEG)
buffer (pH = 9). Ki-67 was visualized by ultraview Uni-
versal HRP/DAB Detection Kit (Ventana Medical Sys-
tems, Tucson, AZ, USA), CD4 and CD8 were visualized
by EnVision + System-HRP (DAB) kits for mouse and
rabbit primary antibodies (Dako, Glostrup, Denmark).
Signal was enhanced by 0.5% copper sulfate and nuclear
staining was performed by Mayer’s Haematoxylin. Ela-
fin/SKALP was visualized by staining with rabbit anti-
goat IgG secondary antibody (A21222, Alexa Fluor
®,
Molecular Probes, Eugene, OR) preceded by blocking of
unspecific binding by normal rabbit serum (X0902,
Dako, Glostrup, Denmark) and signal enhancing by
Image-iT™ FX Signal Enhancer (Molecular Probes,
E u g e n e ,O R ) .h B D - 2w a sv i s u a l i z e db ys t a i n i n gw i t h
Vectastain
® ABC-AP Kit (AK-5005, Vector Laboratories,
Burlingame, CA) and Vector
® Red - Alkaline Phospha-
tase Substrate Kit I (SK-5100, Vector Laboratories, Bur-
lingame, CA), following the manufacturer’s instructions.
Nuclear staining was performed by mounting samples in
Prolong Gold anti-fade reagent (Molecular Probes,
Eugene, OR).
Statistical analyses
The nonparametric Mann-Whitney test was used to
test for differences between treatment groups in semi-
quantitative clinical psoriasis scores. All other p-values
were calculated by a two-tailed Student’s t-test to test
the null hypothesis of no difference between two com-
pared groups. The assumption of equal variances was
tested by the F-test. In all statistical analyses, p-values
< 0.05 were considered significant.
Results
Amelioration of the psoriatic phenotype in xenografted
psoriatic skin following systemic injection of p40-
targeting antibodies
To evaluate the effects of targeting IL-12B mRNA in
psoriatic skin by RNA interference, we wished to
employ the psoriasis xenograft transplantation model in
which psoriatic skin is grafted onto the back of SCID
mice. However, to validate the suitability of this model
for studying the therapeutic efficacy of targeting IL-12B
mRNA, we first treated mice xenotransplanted with
psoriatic skin with the clinically approved p40-targeting
antibody, Ustekinumab. Mice were administered
either p40-targeting antibodies (n = 4) or negative
control (n = 11) (Figure 1a).
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o u tt h es t u d ya n das e m i q u a n t itative clinical psoriasis
score based on erythema, thickness and scaliness of the
psoriatic plaques was recorded twice weekly in a blinded
fashion. After three weeks the mice were sacrificed and
endpoint evaluation of the treatment of psoriasis was
determined histologically by measuring epidermal thick-
ness on three equally distantly cut hematoxylin and
eosin-stained sections of the graft. All sections were
blinded prior to measurements and evaluated randomly.
As evident from Figure 1b, treatment with p40-targeting
antibodies led to a significant improvement of the clini-
cal phenotype of the psoriatic skin compared to the
negative control. This was confirmed by measurements
of the epidermal thickness of the skin grafts at treat-
ment endpoint (Figure 1c). Average epidermal thickness
of the skin grafts were reduced by 38% (438 mm to 273
mm) in the group treated with p40-targeting antibodies
compared to the negative control group (p = 0.039).
In conclusion, the high therapeutic potency of p40-
targeting antibodies validates the relevance of studying
p40-targeting in the xenograft transplantation model.
Potency screening of a panel of IL12B-targeting shRNAs
For cytokine knockdown by RNAi, we have previously uti-
lized a lentiviral vector, originally described by Raoul et al.
[32], in which shRNA expression is driven by the H1 pro-
moter situated in the 3’ LTR of the lentiviral vector. This
design allows duplication of the shRNA expression cassette
upon reverse transcription of vector RNA [8]. However,
shRNA oligonucleotide cloning into this vector was an ela-
borate process involving three cloning steps. To ease this
process we developed a vector (pCCL-PGK-Puro-H1-
MCS) with a multiple cloning site immediately downstream
of the H1 promoter into which annealed shRNA oligonu-
cleotides with compatible overhangs could be directly
cloned (Figure 2a). The generation of the pCCL-PGK-
Puro-H1-MCS vector improved the shRNA oligonucleotide
cloning procedure significantly, supporting a faster and
easier functional screening of lentivirally delivered shRNAs.
To identify potent shRNA variants targeting IL-12B
mRNA, seven target sites in the IL-12B mRNA sequence
were chosen, either predicted by online algorithms or
adapted from previously published efficacious siRNAs.
Four target sequences were located in the coding
sequence and three were located in the 3’ UTR
(Figure 2b). To monitor shRNA knockdown potencies,
each of the seven shRNA sequences were cloned into
pCCL-PGK-Puro-H1-MCS and analyzed for the ability to
t a r g e tt h eI L - 1 2 Bs e q u e n c eb yu s i n gad u a ll u c i f e r a s e
expression assay. By this approach, expression of the
renilla luciferase reporter gene, when fused to the IL-12B
sequence, was responsive to anti-IL12B shRNAs, whereas
expression of the firefly luciferase from the same plasmid
allowed normalization for transfection variations.
HEK293 cells were co-transfected with the psiCHECK-
IL12B plasmid and the plasmid encoding the lentiviral
vector used as an expression plasmid for episomal shRNA
expression. Luciferase activities were measured forty-eight
hours post-transfection and shRNA potencies were deter-
mined by normalizing to the level of expression obtained
with the lentiviral plasmid not expressing any shRNA,
Figure 1 Amelioration of psoriasis by treatment of mice
xenotransplanted with psoriatic skin with systemically
administered p40-targeting antibodies. (a) Schematic schedule
of treatment with p40-targeting antibodies (Ustekinumab). Psoriatic
skin grafts were xenotransplanted onto the back of SCID mice and
allowed to heal for ten days. The mice were then treated by weekly
intraperitoneal injection of p40-targeting antibodies or negative
control. The mice were sacrificed after three weeks of treatment. (b)
Semiquantitative clinical psoriasis scores were given twice weekly
for the three-week treatment duration to mice treated with the
negative control (open circles, n = 11) or p40-targeting antibodies
(open squares, n = 4). Injections were performed at day 0, 7, and
14. All data points are presented as mean ± SEM. *p = 0.003. (c) At
treatment endpoint, mice were sacrificed and biopsies from the skin
grafts were fixed, paraffin-embedded, H&E-stained, and epidermal
thickness was measured in each graft. All data points are presented
as mean + SEM.
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Page 7 of 16utilized here as a negative control (vehicle). An shRNA not
matching any known sequence in the human genome was
used as an additional negative control (shIrrelevant) [39].
As seen in Figure 2c shRNA potencies varied greatly, ran-
ging from almost inactive to 87% down-regulation of the
fusion transcript as seen for shIL12B #6.
Verification of full H1 promoter activity in the pCCL-PGK-
Puro-H1-MCS vector
In the making of the lentiviral vector, pCCL-PGK-Puro-
H1-MCS, for an easy one-step cloning of shRNA oligo-
nucleotides, five base-pairs immediately upstream of the
transcriptional initiation site in the H1 promoter were
modified to accommodate the MCS, leaving the remains
of an AvrII restriction site instead of that of a BglII
restriction site (Figure 2d). It should be noted that the
original lentiviral vector already harbored a 5-bp modifi-
cation compared to the endogenous wild-type H1 pro-
moter, indicating that this 5-bp region did not contain
any cis-acting elements required for H1 promoter
activity. However, to fully verify that shRNA expression
and potency was not affected by this modification, the
lentiviral constructs encoding the two most potent anti-
IL12B shRNAs (#5 and #6) were reverted back to the
original sequence (BglII) as reported by Raoul et al. [32]
by PCR site-directed mutagenesis. The two constructs
with the remains of an AvrII and a BglII restriction site,
respectively, were compared in the dual luciferase assay
(Figure 2e). The two constructs encoding shIL12B #5
did not display any difference in shRNA potency. When
expressed from the context of the new vector containing
the shRNA insertion linker, shIL12B #6 elicited a mar-
ginally improved knockdown of the fusion transcript,
indicating that the 5-bp mutation did not negatively
affect shRNA expression and potency.
Stable IL-12B down-regulation following lentiviral
transduction
To certify that the gene cassette encoding shIL12B #6
was efficiently transferred by the lentiviral vector
Figure 2 Development of a lentiviral vector for an easy one-step shRNA oligonucleotide cloning procedure and potency screening of
a panel of shRNAs targeting human IL-12B. (a) Schematic overview of the lentiviral vector, pCCL-PGK-Puro-H1-MCS, for an easy one-step
shRNA cloning procedure. shRNA oligonucleotides with compatible overhangs can be cloned into the multiple cloning site (MCS) from which
shRNA expression will be driven by the H1 promoter. (b) Schematic overview of IL-12B mRNA and the target sites for the seven designed
shRNAs. (c) Potency screening of seven shRNAs targeting IL-12B mRNA using the dual luciferase assay. HEK293 cells were co-transfected with the
shRNA-encoding lentiviral vector and the psiCHECK-IL12B vector encoding firefly luciferase for transfection normalization and a fusion mRNA
consisting of renilla luciferase and IL-12B. Luciferase activities were measured forty-eight hours post-transfection and renilla luciferase activity was
normalized to firefly luciferase activity and depicted relative to transfection with the empty lentiviral vector, pCCL-PGK-Puro-H1-MCS, not
encoding an shRNA (vehicle). (d) Sequence comparison of the 3’ end of the H1 promoter depicting sequence differences introduced in the H1
promoter for cloning of shRNA oligonucleotides. The TATA box is depicted in bold, and sequence differences are underlined. Furthermore, the
termination signal of the H1 promoter consists of 5 thymines. (e) Confirmation of full promoter activity from the H1 promoter of pCCL-PGK-
Puro-H1-MCS modified to encompass a multiple cloning site for easy one-step cloning of shRNA oligonucleotides. shRNA potency was evaluated
when expressed from the two sequence contexts of the H1 promoter, namely the context described by Raoul et. al. (black bars) and the new
sequence context of the pCCL-PGK-Puro-H1-MCS (white bars). Comparison of shRNA potency was performed using the dual luciferase assay as
described above. All dual luciferase assay experiments were performed at least in triplicates and data are depicted as mean + SEM.
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of the shRNA-expressing vector in experiments that
included the pCCL-PGK-Puro-H1-MCS vector as a
control. High transduction titers of shRNA-expressing
lentiviral vectors were confirmed (ranging from 1.6 ×
10
6 to 5.3 × 10
6 colony-forming units per mL [cfu/
mL] on HeLa cells), although the titers on average
were reduced 4-fold relative to the control vector
which did not express an shRNA (data not shown).
Such findings are in agreement with previous studies
that reported 5- to 6-fold decrease in viral titers pre-
sumably caused by shRNA expression and consequent
targeting of the viral RNA genome during viral vector
production [30].
To evaluate shRNA potency when delivered by lenti-
viral vectors, HEK293 cells were transduced at a multi-
plicity of infection (MOI) of 10 (IU/cell, infectious
units per cell) or at an MOI of << 1 (followed by a
ten-day puromycin selection) to ensure that cells har-
bored only a single lentiviral insertion. The cells were
then transfected with the psiCHECK-IL12B vector one
day and ten days post-transduction, respectively, and
luciferase activities were evaluated forty-eight hours
post-transfection. Knock-down efficiencies of the
fusion transcript are shown in Figure 3a, and it is evi-
dent that the potency of shIL12B #6 was maintained
when delivered by lentiviral transductions at an MOI
of 10. shIL12B #6 mediated a knockdown of 82%
which is comparable to the 87% observed when the
shRNAs were expressed episomally from the trans-
fected plasmid. shRNA expression from a single lenti-
viral insertion mediated a knockdown of 45% of the
fusion transcript, clearly demonstrating the dose-
dependency of shRNAs in mediating RNAi.
To evaluate knockdown of an endogenously
expressed target, which was not in the context of a
fusion mRNA, an IL-12B expression cassette was
inserted into the HeLa cell line by the means of the
Sleeping Beauty DNA transposon system [40]. IL-12B
mRNA expression from the genomically inserted DNA
transposon vector was confirmed by RT-PCR (data not
shown), and the cell line was transduced with the
shRNA-encoding lentiviral vectors at an MOI of 2.
Endogenously expressed IL-12B mRNA was efficiently
targeted by the lentivirally delivered shIL12B #6. The
knockdown potency was evaluated by quantitative RT-
PCR analysis of the transduced cells harvested two
days post-transduction. We detected a 51% knock-
down of IL-12B mRNA transcripts (Figure 3b) which
demonstrated a high potential of lentiviral delivery of
IL12B-directed shRNAs for efficient targeting of aber-
rantly expressed IL-12B for RNAi-mediated down-
regulation.
Figure 3 Confirmation of shRNA potency after lentiviral
delivery. (a) shRNA potency evaluation after transduction with
shRNA-encoding lentiviral vectors. HEK293 cells were transduced at
an MOI of 10 (black bars) or << 1 (white bars) followed by puromycin
selection for ten days to ensure that cells harbored only a single
lentiviral insertion. In the two cases, cells were transfected with the
psiCHECK-IL12B vector one day and ten days post-transduction,
respectively, and luciferase activities were measured forty-eight hours
post-transfection. Renilla luciferase activity was normalized to firefly
luciferase activity and depicted relative to transduction with lentiviral
vectors not encoding an shRNA (vehicle). (b) An IL-12B expressing
HeLa cell line was transduced with shRNA-encoding lentiviral vectors
at an MOI of 2. IL-12B mRNA levels were evaluated by qRT-PCR two
days post-transduction. All assay were performed at least in triplicates
and data are depicted as mean + SEM.
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following intradermal injection of lentiviral vectors in
xenografted human skin
We have previously documented efficient transgene
delivery to xenografted psoriatic skin as confirmed by
high expression of green fluorescent protein (GFP) in
the epidermis and to some extent in the dermis, three
days after intradermal injection of eGFP-encoding lenti-
viral vectors [8]. To evaluate the persistency of trans-
gene expression, luciferase-encoding lentiviral vectors
were intradermally injected in normal human skin xeno-
grafted onto the back of SCID mice. We detected biolu-
minescence from the transduced skin grafts for the
duration of the experiment (98 days) demonstrating
high stability and persistency of reporter gene expres-
sion after a single vector injection (Figure 4a and 4b).
Also, we did not measure any bioluminescence in the
non-transduced grafts or from other tissues of the vec-
tor-treated mice (Figure 4a), demonstrating that vector
transduction was confined to the skin grafts without
apparent spreading of the injected lentiviral vector.
Targeting of IL-12B mRNA in xenografted psoriatic skin
by lentiviral delivery of anti-IL12B shRNAs
To evaluate the effects of targeting IL-12B mRNA in
psoriatic skin, mice xenografted with psoriatic skin were
divided into 4 groups. The first group (n = 11) was
administered a single intradermal dose of lentiviral vec-
tors encoding shIL12B #6 (Figure 5a). The second group
(n = 9) was administered a single dose of lentiviral vec-
tors encoding the irrelevant shRNA (shIrrelevant). The
third group (n = 7) was left untreated and, finally, the
last group of mice (n = 6) was treated daily with the
topically applied class three glucocorticoid steroid Bet-
novat (betamethasone valerate) (Figure 5a), which is a
local treatment used in the clinic to treat mild to mod-
erate psoriasis due to its anti-inflammatory and immu-
nosuppressive properties. At treatment endpoint, RNA
was purified from the skin grafts and RT-PCR con-
firmed the presence of lentiviral transcripts in the skin
(data not shown), corroborating the previous results,
that expression from lentivirus-mediated integration is
persistent during the 3-week treatment period.
As in the Ustekinumab study, the xenografted psoriatic
skin was assessed throughout the study and assigned a
semiquantitative clinical psoriasis score twice weekly in a
blinded fashion. The mice were sacrificed after three weeks
and treatment endpoint evaluation was determined by mea-
suring epidermal thickness and by quantifying IL-12B
mRNA levels in biopsies obtained from the psoriatic skin
grafts. Since skin grafts treated with lentiviral vectors
encoding shIrrelevant and the untreated skin grafts
obtained similar semiquantitative clinical psoriasis scores
for the duration of the experiment (p > 0.35 for all time
points) and displayed similar epidermal thickness (p = 0.22)
as well as similar degree of psorasiform papillae, Monroe’s
absess, vessel formation and parakeratosis, these two groups
were pooled to one group, designated ‘Negative control’.
As evident from Figure 5b, treatment with shIL12B-
encoding lentiviral vectors did not seem to have an
effect on the clinical phenotype of the psoriatic skin
compared to the negative control. On day 3 and 7 we
observed a difference in semiquantitative clinical psoria-
sis score of 0.5 and 0.4, respectively (p = 0.074 and p =
0.069) indicating a slight amelioration of the psoriatic
phenotype. Treatment with the positive control, Betno-
vat, improved the psoriatic phenotype during the treat-
ment course, however, the improvement at treatment
endpoint was not significant (p = 0.12). Average epider-
mal thicknesses are shown in Figure 5c which shows
that grafts injected with shIL12B-encoding lentiviral vec-
tors exhibited a 27% reduction (414 mm to 304 mm) in
average epidermal thickness compared to the negative
control group. However, this reduction did not appear
to be significant (p = 0.10). Betnovat, as expected, eli-
cited a 42% reduction in epidermal thickness (p = 0.04).
In addition to the epidermal thickness, IL-12B mRNA
levels were quantified by qRT-PCR in the skin grafts. As
evident from Figure 5d, treatment with shIL12B-encod-
ing lentiviral vectors elicited a 45% reduction of IL-12B
m R N Ai nt h es k i ng r a f t si na v e r a g e .H o w e v e r ,a si nt h e
case of epidermal thicknesses, this apparent reduction
was not supported by statistical analysis (p = 0.19) prob-
ably ascribable to the limited number of skin grafts.
Finally, we carried out immunohistochemical stain-
ings for characteristic molecular markers of psoriatic
skin (Figure 5e). Neither stainings for Elafin/SKALP
and hBD-2, which are both present in psoriatic but not
in normal skin, nor for the cell proliferation marker
Ki-67 revealed any effect of the treatment with
shIL12B #6 relative to the shIrrelevant control.
Furthermore, staining of skin-homing T-cells by use of
antibodies targeting CD4 and CD8 did not show a dif-
ference between skin grafts treated with shIL12B #6
and shIrrelevant.
In conclusion, we saw only a marginal improvement of
the psoriatic phenotype within the first week after effi-
cient intradermal administration of lentiviral vectors
encoding the highly potent IL12B-targeting shRNA.
Measurements of epidermal thickness and IL-12B
mRNA levels showed reductions of 27% and 45%,
respectively, indicating that the vector-encoded shRNAs
were actively targeting IL-12B mRNA in the skin. In
summary, our data suggest that intradermally adminis-
tered IL12B-targeting shRNAs impact the levels of IL-
12B mRNAs and result in a reduced epidermal thickness
that are very similar to the effects we have previously
reported for shRNAs targeting TNFa mRNA [8].
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Page 10 of 16Figure 4 Efficient and persistent transgene expression after lentiviral transduction of xenografted human skin.N o r m a lh u m a ns k i n
grafts were xenografted onto the back of four SCID mice and three mice were injected a single intradermal dose of firefly luciferase-encoding
lentiviral vectors (three mice to the right in each picture). (a) Representative images of the four mice showing high bioluminescence at day 3,
15, 37, and 98 from the xenografted human skin transduced with luciferase-encoding lentiviral vectors. (b) Bioluminescence from the
xenografted human skin on the three mice injected with luciferase-encoding lentiviral vectors was measured at various time points after
transduction. Data are depicted as mean ± SEM.
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affected by targeting IL-12B mRNA in the psoriasis
xenograft transplantation model.
Discussion
Our research group has previously provided evidence of
the therapeutic efficacy of in vivo knockdown of TNFa
mRNA in human skin facilitated by DNA-encoded
shRNA molecules [8]. This proof-of-concept study con-
firmed the therapeutic applicability of shRNA expression
in skin and documented the potential use of RNAi in
the treatment of psoriasis. In the present study, we
extend the exploration of RNAi-mediated cytokine
knockdown in human skin to include the common sub-
unit of IL-12 and IL-23, p40, encoded by the IL-12B
gene. The p40 subunit is a clinically validated therapeu-
tic target in psoriasis, but it remains unclear if targeting
IL-12B mRNA by RNAi-mediated degradation is thera-
peutically relevant.
The potency of any given shRNA is highly dependent
on target sequence and context. Therefore, initial
screening of a panel of shRNAs is necessary to identify
ah i g h l ya c t i v ev a r i a n t .I n d e e d , in the initial luciferase-
based screening of seven shRNAs targeting IL-12B, one
shRNA candidate was identified, which was able to
mediate a solid down-regulation of the renilla luciferase
gene fused to full length IL-12B cDNA when expressed
from either shRNA-encoding plasmids or lentiviral vec-
tors. High shRNA potency was confirmed when the
shRNA was expressed from a single lentiviral integration
and after extrachromosomal non-integrated lentiviral
vectors had been lost. Additionally, the highly varying
potencies of the seven shRNA candidates confirmed the
general need to improve the in silico algorithms for
rational target prediction to minimize the initial screen-
ing work load in the identification of potent shRNA
candidates. Furthermore, we found that the two already
published siRNAs that efficiently target the murine [36]
and human IL-12B [37] sequences, respectively, could
not be successfully adapted to an shRNA context and
maintain potency. We explain this by species sequence
and target context variations and also by the fact that
Figure 5 In vivo knockdown of IL-12B in xenografted psoriatic skin by lentiviral delivery of anti-IL12B shRNAs. (a) Schematic schedule of
treatment with shRNA-encoding lentiviral vectors (upper panel) and topically applied steroid (lower panel). Psoriatic skin grafts were xenografted
onto the back of SCID mice and allowed to heal for ten days. The skin grafts were then either left untreated or treated by a single intradermal
injection of lentiviral vectors encoding either shIL12B #6 or an irrelevant shRNA, or treated daily with the topically applied class three steroid,
Betnovat (positive control). The mice were sacrificed three weeks after treatment. The two groups consisting of untreated mice and mice treated
with lentiviral vectors encoding an irrelevant shRNA were pooled to a single group (negative control) due to high similarities in the
semiquantitative clinical psoriasis scores and epidermal thicknesses. (b) Semiquantitative clinical psoriasis scores were given twice weekly for the
three-week treatment duration to mice treated with negative control (open circles, n = 16), LV-shIL12B #6 (open squares, n = 11), or Betnovat
(crosses, n = 6). Intradermal injections were performed at day 0. All data points are presented as mean ± SEM. *p = 0.86, **p = 0.12. (c) At
treatment endpoint three weeks post-transduction of the skin grafts, mice were sacrificed and biopsies from the skin grafts were fixed, paraffin-
embedded, H&E-stained, and epidermal thickness was measured in each graft. (d) Biopsies from the xenografted psoriatic skin injected with
shRNA-encoding lentiviral vectors were acquired at treatment endpoint three weeks post-transduction and evaluated for IL-12B gene expression
by qRT-PCR. Data are presented as mean + SEM. (e) Immunohistochemical stainings were performed for Ki-67, CD4, CD8, SKALP/Elafin, and hBD2
on skin sections treated with LV-shIrrelevant or LV-shIL12B #6.
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sequence-dependent which could adversely affect the
potency of an siRNA in an shRNA context.
Variations in target accessibility in the fusion mRNA
context could influence RNAi activity and thus provide
a false measurement of shRNA potency. This empha-
sizes the need to validate shRNA potency on native
endogenously expressed targets. Moving the experimen-
tal setup to endogenously expressed targets showed that
shRNA potencies were maintained even when shRNAs
were expressed from few lentiviral insertions. High
shRNA potency at low cellular concentrations is highly
relevant for in vivo transduction of a tissue where
there are a high number of target cells and cell accessi-
bility is hampered compared to in vitro grown cells in
monolayer.
The psoriasis xenograft transplantation model cur-
rently appears to be the best tool to screen anti-psoriatic
therapeutic strategies in psoriasis before introducing
them into to the clinic [41]. Many already established
anti-psoriatic therapies show similar results in the psor-
iasis xenotransplantation model as in the clinic. In line
with these findings, we valid a t e dt h a tt h ec l i n i c a l l y
approved p40-targeting antibody, Ustekinumab, led to a
significant improvement of the psoriatic phenotype as
evaluated by the semi-quantitative clinical psoriasis
score and measurements of epidermal thickness in the
psoriasis xenograft transplantation model.
Using the psoriasis xenograft transplantation model, we
wished to evaluate if lentiviral delivery of shIL12B #6
could lower IL-12B mRNA levels and if this would have a
beneficial effect on the disease phenotype. We found that
IL-12B mRNA levels were reduced by 45% in the
shIL12B-receiving skin grafts compared to the negative
control. This result pointed towards the establishment of a
stable knockdown of IL-12B which is consistent with our
previous in vivo study of TNFa knockdown in human skin
[8]. Dendritic cells and macrophages in the upper dermal
compartment (papillary dermis), and to some extent in the
epidermis, have been shown to be the main source of IL-
12 and IL-23, but epidermal keratinocytes also express
both interleukins to a lesser extent [16]. We have pre-
viously established that lentiviral vector-mediated eGFP
transfer to xenografted psoriatic skin is more efficient in
the epidermal compartment than the dermal compartment
[8] and in our current setup, this could mean that interfer-
ing with IL-12B production in dermal dendritic cells and
macrophages was limited by poor shRNA delivery. In con-
trast, the efficient transduction of epidermal keratinocytes
implied that IL-12B knockdown in these cells was not lim-
ited by shRNA delivery.
Epidermal keratinocytes in psoriatic lesions have a
transit time of 4-7 days from the basal layer to the stra-
tum corneum meaning that the keratinocytes have been
replenished several times during the three-week treat-
ment [42]. Hence, in order to stably knock down aber-
rant levels of IL-12B produced by epidermal
keratinocytes throughout the treatment course, an effi-
cient transduction of epidermal stem cells is required.
Indeed, persistence of transgene expression from lentivi-
rally transduced xenografted normal human skin was
shown beyond the time span of keratinocyte transition
from the basal membrane to the stratum corneum,
implying that skin stem cells in the basal compartment
were efficiently transduced (Figure 4).
Increased epidermal thickness is an important diag-
nostic hallmark of psoriasis and stable IL-12B knock-
down seemed to result in a reduction in epidermal
thickness by 27% (414 mm to 304 mm) in skin trans-
duced with shIL12B-encoding lentiviral vectors com-
pared to controls. This finding could be indicative of
altered epidermal cell kinetics although no difference
was seen in the immunohistochemical staining for the
proliferative marker Ki-67. Nevertheless, a resulting clin-
ical disease improvement was not apparent at treatment
end-point even though a strong tendency towards this
was seen at day 3 and 7 in the treatment course.
We have previously shown that TNFa mRNA knock-
down in the psoriasis xenograft transplantation model has
a significant positive effect on the clinical psoriatic pheno-
type throughout the treatment course [8]. When compared
to the present study, knockdown of target mRNAs (IL-12B
and TNFa mRNA, respectively) and the following reduc-
tion in epidermal thickness were comparable (Figure 6) [8].
This indicates that both cytokines can be efficiently targeted
by shRNAs with a resultant epidermal remodeling, but that
only TNFa knockdown results in a clinical improvement of
the psoriatic phenotype within the experimental time
frame. It should be kept in mind that the clinical observa-
tion is only a superficial score, and cannot reflect the dis-
ease status in the deeper layers. The large variations in the
semiquantitative clinical psoriasis scores also confirm this.
E.g. a scale that has yet not sloughed off may hide a more
alleviated disease state of the skin, but is not registered in
the clinical score. More emphasis must therefore be given
to the epidermal thickness measurements as this measure
gives a more in-depth evaluation of the disease.
TNFa mRNA knockdown has a significant positive
effect on the clinical psoriatic phenotype throughout the
treatment course, whereas the effect of IL-12B mRNA
knockdown in the current study is minimal. Such differ-
ence between targeting of IL-12B and of TNFa could
hypothetically be explained by the different functions of
the two cytokines. If IL-12 and IL-23 are less potent
immune mediators than TNFa is, then TNFa knockdown
may have a more profound therapeutic effect on psoriasis.
The cytokines may also differ in abundance and redun-
dancy, as well as the dynamics and kinetics of their
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source of the aberrant expression of TNFa and IL-12B is
somewhat similar [43]. Therefore, although a difference in
transduction efficiency of the various cellular constituents
of the skin could influence the response to different cyto-
kine-directed shRNAs, this may not necessarily explain
our findings. Alternatively, the variation between cytokine
targets may reflect differences in cytokine mRNA expres-
sion levels and, thus, the knockdown efficiencies that are
required to obtain a therapeutic benefit. Although sys-
temic treatment with anti-p40 monoclonal antibodies
resulted in robust clinical improvement in the xenotrans-
plantation model, we cannot exclude the possibility that a
local RNA-directed treatment targeting IL-12B would
require a longer time-frame (> 3 weeks to obtain a thera-
peutic effect and improve the disease phenotype.
The skin offers an attractive organ for RNAi-based
therapeutics due to its ease of access. A therapeutic
approach relying on lentiviral vector-mediated delivery
of shRNAs to the skin is far from clinically relevant due
to safety issues concerning the vector. So far, topical
n o n - v i r a ld e l i v e r yo fR N A ie f f e c t o r sh a v eb e e nh a m -
pered by poor penetrability of the stratum corneum, but
recent advances have made it possible to deliver siRNAs
formulated in a cream to the epidermis and dermis of
murine skin at therapeutically relevant levels [44]. Even
though topical local delivery of siRNAs does not
mediate a sustained RNAi effect, it has the potential to
overcome multiple problems regarding systemic biologi-
cal therapeutics including complications concerning
patient-friendly administration, contra-indications, side-
effects and patient adherence. Based on our current
knowledge, we suggest that siRNAs targeting TNFa
rather than IL-12B are further explored for clinical use.
Conclusion
Our studies show potent and sustained RNAi-mediated
down-regulation of IL-12B mRNA by the use of lentiviral
vectors. We document efficient lentiviral-mediated gene
delivery and persistent gene expression in xenografted
human skin. Down-regulation of IL-12B mRNA in xeno-
grafted psoriatic skin leads to a decrease in epidermal
thickness, but not a clinical amelioration of the psoriatic
phenotype in contrast to our previous studies targeting
TNFa mRNA. Our studies question IL-12B mRNA as an
optimal target for RNAi-directed treatment and, hence,
further strengthen the need for validating therapeutic tar-
gets for such treatment. Small RNAs that mediate a cyto-
kine-targeting RNAi response or interfere with
endogenous cytokine regulation have the potential to
become novel anti-inflammatory therapeutics, but addi-
tional obstacles such as off-targeting effects and poor
delivery must be addressed before small RNAs can prove
their therapeutic worth.
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